# Rhythm Pharmaceuticals Inc. (RYTM) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $102.74, market value $7.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Rhythm Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 29.5×**. Each dollar of revenue is priced at 29.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 68.7×**. The shares trade at 68.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Operating margin: -83.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -103.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -141.3%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -82.1%**. Return on all capital, debt included, is -82.1%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -42.8%**. Each dollar of assets produces -42.8% of profit.

## Growth
- **Revenue growth (1 yr): 45.8%** (3-yr 100.2%/yr). Revenue grew 45.8% over the last year.
- **EPS growth (1 yr): 28.3%**. Earnings per share rose 28.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.78**. Debt is 0.78 times equity, moderate leverage.
- **Altman Z-score: 19.68**. A Z-score of 19.68 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Rhythm Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (16 analysts). 16 analysts cover Rhythm Pharmaceuticals Inc.; the consensus is buy, with an average price target of $140.19 (+36% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -1.8%** (YTD -4.0%, 3-mo 18.9%). The shares are down 1.8% over twelve months including dividends.
- **From 52-week high: -15.9%** (37.9% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 38**. An RSI of 38 is neutral.
- **Beta (1 yr): 0.99** (volatility 46%). Beta of 0.99 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RYTM · Page: https://foliofundamentals.com/stocks/rytm

Not investment advice.